BE1218

CAS No. 2893967-40-1

BE1218( —— )

Catalog No. M35749 CAS No. 2893967-40-1

BE1218 is a liver X receptor (LXR) inverse agonist, active on LXRα and LXRβ, with IC50 values of 9 nM and 7 nM, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 71 In Stock
5MG 92 In Stock
10MG 147 In Stock
25MG 250 In Stock
50MG 365 In Stock
100MG 524 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BE1218
  • Note
    Research use only, not for human use.
  • Brief Description
    BE1218 is a liver X receptor (LXR) inverse agonist, active on LXRα and LXRβ, with IC50 values of 9 nM and 7 nM, respectively.
  • Description
    BE1218 is a liver X receptor (LXR) inverse agonist with IC50 values of 9 nM and 7 nM against LXRα and LXRβ, respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Liver X Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2893967-40-1
  • Formula Weight
    551.69
  • Molecular Formula
    C30H30FNO4S2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 33.33 mg/mL (60.41 mM; Ultrasonic (<60°C)
  • SMILES
    N(S(=O)(=O)C1=C(C)C=C(C)C=C1C)(CC2=CC=C(C=C2)C3=CC(S(C)(=O)=O)=CC=C3)CC4=C(F)C=CC=C4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Elgendy B, et al. Synthesis and structure activity relationship of the first class of LXR inverse agonists. Bioorg Chem. 2022 Feb;119:105540.?
molnova catalog
related products
  • Sesamin

    Extracted from Sesamum indicum L.

  • Myclobutanil

    Myclobutanil is a triazole chemical used as a fungicide. It is a steroid demethylation inhibitor, specifically inhibiting ergosterol biosynthesis.

  • 30-Hydroxygambogic a...

    30-Hydroxygambogic acid exhibits significant cytotoxicities against the human leukemia K562/S and the corresponding doxorubicin-resistant K562/R cell lines.